Advanced search
Publication Cover
HIV Clinical Trials Volume 2, 2001 - Issue 2
Submit an article Journal homepage
37
Views
26
CrossRef citations to date
0
Altmetric
Original Articles

Circulating Levels of Interleukin-7 in Antiretroviral-Naïve and Highly Active Antiretroviral Therapy-Treated HIV-Infected Patients

Claudio M. MastroianniDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy
,
Gabriele ForcinaDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy
,
Gabriella d’EttorreDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy
,
Miriam LichtnerDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy
,
Fabio MengoniDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy
,
Claudia D’AgostinoDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, Italy
&
Vincenzo VulloDepartment of Infectious and Tropical Diseases, La Sapienza University, Rome, ItalyCorrespondence[email protected].
 show all
Pages 108-112 | Published online: 29 Jan 2015

REFERENCES

  • Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123–126.
  • McCune JM, Loftus R, Schmidt DK, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest. 1998;101:2301–2308.
  • McCune JM. Reappraising T-cell turnover and thymic function in HIV disease. HIV: Adv Res Ther. 1999;9:1–7.
  • Douek D, McFarland R, Keiser P, et al. Changes in thymic function with age and during treatment of HIV infection. Nature. 1998;396:690–695.
  • Hofmeister R, Khaled AR, Benbernou N, Rajnavolgyi E, Muegge K, Durum SK. Interleukin-7: Physiological roles and mechanisms of action. Cytokine Growth Factor Rev. 1999;10:41–60.
  • Appasamy PM. Biological and clinical implications of interleukin-7 and lymphopoiesis. Cytokines Cell Mol Ther. 1999;5:25–39.
  • von Freeden-Jeffry U, Solvason N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for BcI-2-expression and normal cell cycle progression. Im-munity. 1997;7:147–154.
  • Amos CL, Woetmann A, Nielsen M, et al. The role of caspase 3 and Bclx in the action of interleukin-7 (IL-7): A survival factor in activated human T cells. Cytokine. 1998;10:662–668.
  • Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood. 1996;88:1887–1894.
  • Bolotin Z, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: Relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999;23:783–788.
  • Puel A, Leonard WJ. Mutations in the gene for the IL-7 receptor result in T-B+NK+ severe combined immunodefi-ciency disease. Curr Opin Immunol. 2000;12:468–473.
  • Napolitano LA, Grant RM, Deeks SG, et al. Increased pro-duction of IL-7 accompanies H IV-1-mediated T-cell deple-tion: Implications for T-cell homeostasis. Nat Med. 2001;7: 73–79.
  • Fry TJ, Connick E, Landay A, et al. A potential role for IL-7 in T-cell homeostasis in HIV infected patients. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract LB1.
  • Carini C, McLane MF, Mayer KH, Essex M. Dysregulation of interleukin-7 receptors may generate loss of cytotoxic T-cell response in human immunodeficiency virus type C infection. Eur J Immunol. 1994;24:2927–2934.
  • Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-in-fected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis. 1999;179:74–82.
  • Okamoto K, Douek DC, McFarland RD, Koup RA. Increas-ing thymic output with exogenous IL-7. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 30—February 2, 2000; San Francisco, CA. Abstract 326.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.